Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tacrolimus, an immunosuppressive treatment to help prevent rejection of a kidney or liver transplant
Subscribe to our email newsletter
Sandoz has launched tacrolimus capsules, a generic equivalent of Prograf, in the US. Tacrolimus is an immunosuppressive treatment to help prevent rejection of a kidney or liver transplant.
According to IMS Health, Prograf had US sales of $929m for the 12 months through April 2009. Sandoz will market tacrolimus in capsules of 0.5, 1 and 5mg strengths.
Jeff George, CEO of Sandoz, said: Tacrolimus is an important new product for Sandoz, further strengthening our diverse portfolio of affordable medicines in the key US market.
Sandoz is excited to offer this new high-quality, affordable treatment option to transplant patients. Sandoz and our parent company Novartis have deep experience in the transplant field and we are deeply committed to providing more cost-saving treatment options for this community in the future, he added.